HawkeyC, KahanA, SteinbruckK. Gastrointestinal tolerability of the COX-2 inhibitor, meloxicam, in osteoarthritis patients: the meloxicam large scale international study safety assessment (MELISSA). Br J Rheumatol1998; 37:937–45.
5.
EhrichEW, DallobA, DeLepelaireI. Characterisation of rofecoxib as a cyclo-oxygenase-2 isoform inhibitor and demonstration of analgesia in the dental pain model. Clin Pharmacol Ther1999; 65:336–47.
6.
HubbardRC, GeissGS, WoodsEM. Efficacy, tolerability and safety of celecoxib a specific COX-2 inhibitor in osteoarthritis. Rheumatol Eur1998; 27(suppl 1):118.
7.
CannonG, CaldwellJ, HoltP. MK-0966, a specific COX-2 inhibitor has clinical efficacy comparable to diclofenac in the treatment of knee and hip OA in a 26 week controlled clinical trial. Arthritis Rheum1998; 41(suppl 9):S83.
8.
GeissGS, HubbardRC, CallisonDA. Safety and efficacy of celecoxib, a specific COX-2 inhibitor. Rheumatol Eur1998; 27(suppl 1):118.
9.
GeissGS, SteadH, MorantSV. Endoscopic and tolerability results from a study of celecoxib, a specific COX-2 inhibitor, in patients with RA. Rheumatol Eur1998; 27(suppl 1):118.
10.
HawkeyC, LaineL, BeaulieuAD. Treatment of osteoarthritis with rofecoxib, a cox-2 specific inhibitor, was associated with a lower incidence of gastroduodenal ulcers compared to ibuprofen and was comparable to placebo treatment. Ann Rheum Dis EULAR1999; 207:861.
11.
LangmanM, JensenDM, WatsonDJ. Lower incidence of clinically evident upper GI perforations, ulcers and bleeds in patients treated with rofecoxib vs nonspecific cyclooxygenase inhibitors. Ann Rheum Dis EULAR1999; 207:862.
12.
SteinerG, Tohidast-AkradM, WitzmannG. Cytokine production by synovial T cells in rheumatoid arthritis. Rheumatology1999; 38:202–13.
13.
MannaSK and AggarwalBB. Immunosuppressive leflunomide metabolite (A77 1726) blocks TNF-dependent nuclear factor-kappa B activation and gene expression. J Immunol1999; 162:2095–102.
14.
SmolenJS, KaldenJR, ScottDL. Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. Lancet1999; 353:259–66.
15.
WeinblattME, KremerJM, CoblynJS. Pharmacokinetics, safety, and efficacy of combination treatment with methotrexate and leflunomide in patients with active rheumatoid arthritis. Arthritis Rheum1999; 42:1322–8.
16.
SnowdenJ, BrookesPM and BiggsJC. Haemopoietic stem cell transplantation for autoimmune disease. Br J Haematol1997; 99:9–22.
17.
TyndallA. Haematological stem cell transplantation in the treatment of severe autoimmune diseases: first experiences from an international project. Rheumatology1999; 38:774–6.
18.
LowenthalRM, CohenML, AtkinsonK. Apparent cure of rheumatoid arthritis by bone marrow transplantation. J Rheumatol1993; 20:137.
19.
McGonagleD, RawstonA, RichardsS. A phase 1 study to address the safety and efficacy of G-CSF for the mobilisation of haematopoietic progenitor cells in active RA. Arthritis Rheum1997; 40:1838–42.
20.
ElliottMJ, MainiRN, FeldmannM. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritis. Lancet1994; 344:1105–10.
21.
MainiRN, BreedveldFC, KaldenJR. Therapeutic efficacy of multiple intravenous infusions of anti-tumour necrosis factor α monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum1998; 41:1552–63.
22.
MorelandLW, SchiffMH, BaumgartnerSW. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med1999; 130:478–86.
23.
WeinblattME, KremerJM, BankhurstAD. A trial of etanercept, a recombinant tumour necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med1999; 340:253–9.
24.
TilleyBC, AlarconGSHeyse SP et al; for the MIRA Trial Group. Minocycline in rheumatoid arthritis: a 48–week, double-blind, placebo-controlled trial. Ann Intern Med1995; 122:81–9.
25.
O'DellJR, HaireCE, PalmerW. Treatment of early rheumatoid arthritis with minocycline or palcebo: results of a randomised, double-blind, palcebo-controlled trial. Arthritis Rheum1997; 40:842–48.
26.
TrenthamDE, Dynesius-TrenthamRA. Antibiotic therapy for rheumatoid arthritis: scientific and anecdotal appraisals. Rheum Dis Clin North Am1995; 21:817–34.
27.
TanEM, CohenAS, FriesJF. The 1982 revised criteria for the classification of systemic lupus erythematosus (SLE). Arthritis Rheum1982; 25:1271–7.
28.
Calvo-AlenJ, BastianHM, StraatonKV. Identification of patient subsets among those presumptively diagnosed with, referred, and / or followed up for systemic lupus erythematosus at a large tertiary care center. Arthritis Rheum1995; 38:1475–84.
Cohen TervaertJW, HuitemaMG, HeneRJ. Prevention of relapses of Wegener's granulomatosis by treatment based on anti-neutrophil cytoplasmic antibody titre. Lancet1990; 336:709–11.
31.
KerrGS, FleisherTA, HallahanCW. Limited prognostic value of changes in antineutrophil cytoplasmic antibody titre in patients with Wegener's granulomatosis. Arthritis Rheum1993; 36:365–71.
32.
GordonM, LuqmaniRA, AduD. Relapses in patients with a systemic vasculitis. QJM1993; 86:779–89.
33.
HagenEC, DahaMR, HermansJ. Diagnostic value of standardized assays for anti-neutrophil cytoplasmic antibodies in idiopathic systemic vasculitis. EC/BCR Project for ANCA Assay Standardization. Kidney Int1998; 53:743–53.
34.
WestmanKW, BygrenPG, EilertI. Rapid screening assay for anti-GBM antibody and ANCAs; an important tool for the differential diagnosis of pulmonary renal syndromes. Nephrol Dial Transplant1997; 12:1863–8.
35.
KhamashataMA, CuadradoMJ, MujicF. The management of thrombosis in the antiphospholipid-antibody syndrome. New Engl J Med1995; 332:993–7.
36.
LiggettNW, ReidDM. Osteoporosis and its management. Hosp Med1999; 60:238–42.
